Standard steroid treatment for autoimmune pancreatitis

T. Kamisawa, T. Shimosegawa, K. Okazaki, T. Nishino, H. Watanabe, A. Kanno, F. Okumura, T. Nishikawa, K. Kobayashi, T. Ichiya, H. Takatori, K. Yamakita, K. Kubota, H. Hamano, K. Okamura, K. Hirano, Tetsuhide Ito, S. B.H. Ko, M. Omata

Research output: Contribution to journalArticle

422 Citations (Scopus)

Abstract

Objective: To establish an appropriate steroid treatment regimen for autoimmune pancreatitis (AIP). Methods: A retrospective survey of AIP treatment was conducted in 17 centres in Japan. The main outcome measures were rate of remission and relapse. Results: Of 563 patients with AIP, 459 (82%) received steroid treatment. The remission rate of steroid-treated AIP was 98%, which was significantly higher than that of patients without steroid treatment (74%, 77/104; p<0.001). Steroid treatment was given for obstructive jaundice (60%), abdominal pain (11%), associated extrapancreatic lesions except the biliary duct (11%), and diffuse enlargement of the pancreas (10%). There was no relationship between the period necessary to achieve remission and the initial dose (30 mg/day vs 40 mg/day) of prednisolone. Maintenance steroid treatment was given in 377 (82%) of 459 steroid-treated patients, and steroid treatment was stopped in 104 patients. The relapse rate of patients with AIP on maintenance treatment was 23% (63/273), which was significantly lower than that of patients who stopped maintenance treatment (34%, 35/104; p=0.048). From the start of steroid treatment, 56% (55/99) relapsed within 1 year and 92% (91/99) relapsed within 3 years. Of the 89 relapsed patients, 83 (93%) received steroid re-treatment, and steroid re-treatment was effective in 97% of them. Conclusions: The major indication for steroid treatment in AIP is the presence of symptoms. An initial prednisolone dose of 0.6 mg/kg/day, is recommend, which is then reduced to a maintenance dose over a period of 3-6 months. Maintenance treatment with low-dose steroid reduces but dose not eliminate relapses.

Original languageEnglish
Pages (from-to)1504-1507
Number of pages4
JournalGut
Volume58
Issue number11
DOIs
Publication statusPublished - Nov 1 2009

Fingerprint

Pancreatitis
Steroids
Therapeutics
Prednisolone
Recurrence
Obstructive Jaundice
Abdominal Pain
Pancreas
Japan
Maintenance
Outcome Assessment (Health Care)

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

Kamisawa, T., Shimosegawa, T., Okazaki, K., Nishino, T., Watanabe, H., Kanno, A., ... Omata, M. (2009). Standard steroid treatment for autoimmune pancreatitis. Gut, 58(11), 1504-1507. https://doi.org/10.1136/gut.2008.172908

Standard steroid treatment for autoimmune pancreatitis. / Kamisawa, T.; Shimosegawa, T.; Okazaki, K.; Nishino, T.; Watanabe, H.; Kanno, A.; Okumura, F.; Nishikawa, T.; Kobayashi, K.; Ichiya, T.; Takatori, H.; Yamakita, K.; Kubota, K.; Hamano, H.; Okamura, K.; Hirano, K.; Ito, Tetsuhide; Ko, S. B.H.; Omata, M.

In: Gut, Vol. 58, No. 11, 01.11.2009, p. 1504-1507.

Research output: Contribution to journalArticle

Kamisawa, T, Shimosegawa, T, Okazaki, K, Nishino, T, Watanabe, H, Kanno, A, Okumura, F, Nishikawa, T, Kobayashi, K, Ichiya, T, Takatori, H, Yamakita, K, Kubota, K, Hamano, H, Okamura, K, Hirano, K, Ito, T, Ko, SBH & Omata, M 2009, 'Standard steroid treatment for autoimmune pancreatitis', Gut, vol. 58, no. 11, pp. 1504-1507. https://doi.org/10.1136/gut.2008.172908
Kamisawa T, Shimosegawa T, Okazaki K, Nishino T, Watanabe H, Kanno A et al. Standard steroid treatment for autoimmune pancreatitis. Gut. 2009 Nov 1;58(11):1504-1507. https://doi.org/10.1136/gut.2008.172908
Kamisawa, T. ; Shimosegawa, T. ; Okazaki, K. ; Nishino, T. ; Watanabe, H. ; Kanno, A. ; Okumura, F. ; Nishikawa, T. ; Kobayashi, K. ; Ichiya, T. ; Takatori, H. ; Yamakita, K. ; Kubota, K. ; Hamano, H. ; Okamura, K. ; Hirano, K. ; Ito, Tetsuhide ; Ko, S. B.H. ; Omata, M. / Standard steroid treatment for autoimmune pancreatitis. In: Gut. 2009 ; Vol. 58, No. 11. pp. 1504-1507.
@article{17aee9c6b6f345a88071c19f39fc285c,
title = "Standard steroid treatment for autoimmune pancreatitis",
abstract = "Objective: To establish an appropriate steroid treatment regimen for autoimmune pancreatitis (AIP). Methods: A retrospective survey of AIP treatment was conducted in 17 centres in Japan. The main outcome measures were rate of remission and relapse. Results: Of 563 patients with AIP, 459 (82{\%}) received steroid treatment. The remission rate of steroid-treated AIP was 98{\%}, which was significantly higher than that of patients without steroid treatment (74{\%}, 77/104; p<0.001). Steroid treatment was given for obstructive jaundice (60{\%}), abdominal pain (11{\%}), associated extrapancreatic lesions except the biliary duct (11{\%}), and diffuse enlargement of the pancreas (10{\%}). There was no relationship between the period necessary to achieve remission and the initial dose (30 mg/day vs 40 mg/day) of prednisolone. Maintenance steroid treatment was given in 377 (82{\%}) of 459 steroid-treated patients, and steroid treatment was stopped in 104 patients. The relapse rate of patients with AIP on maintenance treatment was 23{\%} (63/273), which was significantly lower than that of patients who stopped maintenance treatment (34{\%}, 35/104; p=0.048). From the start of steroid treatment, 56{\%} (55/99) relapsed within 1 year and 92{\%} (91/99) relapsed within 3 years. Of the 89 relapsed patients, 83 (93{\%}) received steroid re-treatment, and steroid re-treatment was effective in 97{\%} of them. Conclusions: The major indication for steroid treatment in AIP is the presence of symptoms. An initial prednisolone dose of 0.6 mg/kg/day, is recommend, which is then reduced to a maintenance dose over a period of 3-6 months. Maintenance treatment with low-dose steroid reduces but dose not eliminate relapses.",
author = "T. Kamisawa and T. Shimosegawa and K. Okazaki and T. Nishino and H. Watanabe and A. Kanno and F. Okumura and T. Nishikawa and K. Kobayashi and T. Ichiya and H. Takatori and K. Yamakita and K. Kubota and H. Hamano and K. Okamura and K. Hirano and Tetsuhide Ito and Ko, {S. B.H.} and M. Omata",
year = "2009",
month = "11",
day = "1",
doi = "10.1136/gut.2008.172908",
language = "English",
volume = "58",
pages = "1504--1507",
journal = "Gut",
issn = "0017-5749",
publisher = "BMJ Publishing Group",
number = "11",

}

TY - JOUR

T1 - Standard steroid treatment for autoimmune pancreatitis

AU - Kamisawa, T.

AU - Shimosegawa, T.

AU - Okazaki, K.

AU - Nishino, T.

AU - Watanabe, H.

AU - Kanno, A.

AU - Okumura, F.

AU - Nishikawa, T.

AU - Kobayashi, K.

AU - Ichiya, T.

AU - Takatori, H.

AU - Yamakita, K.

AU - Kubota, K.

AU - Hamano, H.

AU - Okamura, K.

AU - Hirano, K.

AU - Ito, Tetsuhide

AU - Ko, S. B.H.

AU - Omata, M.

PY - 2009/11/1

Y1 - 2009/11/1

N2 - Objective: To establish an appropriate steroid treatment regimen for autoimmune pancreatitis (AIP). Methods: A retrospective survey of AIP treatment was conducted in 17 centres in Japan. The main outcome measures were rate of remission and relapse. Results: Of 563 patients with AIP, 459 (82%) received steroid treatment. The remission rate of steroid-treated AIP was 98%, which was significantly higher than that of patients without steroid treatment (74%, 77/104; p<0.001). Steroid treatment was given for obstructive jaundice (60%), abdominal pain (11%), associated extrapancreatic lesions except the biliary duct (11%), and diffuse enlargement of the pancreas (10%). There was no relationship between the period necessary to achieve remission and the initial dose (30 mg/day vs 40 mg/day) of prednisolone. Maintenance steroid treatment was given in 377 (82%) of 459 steroid-treated patients, and steroid treatment was stopped in 104 patients. The relapse rate of patients with AIP on maintenance treatment was 23% (63/273), which was significantly lower than that of patients who stopped maintenance treatment (34%, 35/104; p=0.048). From the start of steroid treatment, 56% (55/99) relapsed within 1 year and 92% (91/99) relapsed within 3 years. Of the 89 relapsed patients, 83 (93%) received steroid re-treatment, and steroid re-treatment was effective in 97% of them. Conclusions: The major indication for steroid treatment in AIP is the presence of symptoms. An initial prednisolone dose of 0.6 mg/kg/day, is recommend, which is then reduced to a maintenance dose over a period of 3-6 months. Maintenance treatment with low-dose steroid reduces but dose not eliminate relapses.

AB - Objective: To establish an appropriate steroid treatment regimen for autoimmune pancreatitis (AIP). Methods: A retrospective survey of AIP treatment was conducted in 17 centres in Japan. The main outcome measures were rate of remission and relapse. Results: Of 563 patients with AIP, 459 (82%) received steroid treatment. The remission rate of steroid-treated AIP was 98%, which was significantly higher than that of patients without steroid treatment (74%, 77/104; p<0.001). Steroid treatment was given for obstructive jaundice (60%), abdominal pain (11%), associated extrapancreatic lesions except the biliary duct (11%), and diffuse enlargement of the pancreas (10%). There was no relationship between the period necessary to achieve remission and the initial dose (30 mg/day vs 40 mg/day) of prednisolone. Maintenance steroid treatment was given in 377 (82%) of 459 steroid-treated patients, and steroid treatment was stopped in 104 patients. The relapse rate of patients with AIP on maintenance treatment was 23% (63/273), which was significantly lower than that of patients who stopped maintenance treatment (34%, 35/104; p=0.048). From the start of steroid treatment, 56% (55/99) relapsed within 1 year and 92% (91/99) relapsed within 3 years. Of the 89 relapsed patients, 83 (93%) received steroid re-treatment, and steroid re-treatment was effective in 97% of them. Conclusions: The major indication for steroid treatment in AIP is the presence of symptoms. An initial prednisolone dose of 0.6 mg/kg/day, is recommend, which is then reduced to a maintenance dose over a period of 3-6 months. Maintenance treatment with low-dose steroid reduces but dose not eliminate relapses.

UR - http://www.scopus.com/inward/record.url?scp=70350212636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350212636&partnerID=8YFLogxK

U2 - 10.1136/gut.2008.172908

DO - 10.1136/gut.2008.172908

M3 - Article

C2 - 19398440

AN - SCOPUS:70350212636

VL - 58

SP - 1504

EP - 1507

JO - Gut

JF - Gut

SN - 0017-5749

IS - 11

ER -